These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 1370701)

  • 21. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
    Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
    Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of proliferating cell nuclear antigen (PC10), p53 protein and c-erbB-2 in renal adenocarcinoma.
    Lipponen P; Eskelinen M; Hietala K; Syrjänen K; Gambetta RA
    Int J Cancer; 1994 Apr; 57(2):275-80. PubMed ID: 7908898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma--an immunocytochemical study.
    Gasparini G; Gullick WJ; Maluta S; Dalla Palma P; Caffo O; Leonardi E; Boracchi P; Pozza F; Lemoine NR; Bevilacqua P
    Eur J Cancer; 1994; 30A(1):16-22. PubMed ID: 7908213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. c-erbB growth-factor-receptor proteins in ovarian tumours.
    Simpson BJ; Phillips HA; Lessells AM; Langdon SP; Miller WR
    Int J Cancer; 1995 Jun; 64(3):202-6. PubMed ID: 7622309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncogene proteins and proliferation antigens in thymomas: increased expression of epidermal growth factor receptor and Ki67 antigen.
    Gilhus NE; Jones M; Turley H; Gatter KC; Nagvekar N; Newsom-Davis J; Willcox N
    J Clin Pathol; 1995 May; 48(5):447-55. PubMed ID: 7629292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of her-2/neu in human prostate cancer and benign hyperplasia.
    Gu K; Mes-Masson AM; Gauthier J; Saad F
    Cancer Lett; 1996 Feb; 99(2):185-9. PubMed ID: 8616823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content.
    Prat J; Oliva E; Lerma E; Vaquero M; Matías-Guiu X
    Cancer; 1994 Sep; 74(6):1778-83. PubMed ID: 7915964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunolocalization of epidermal growth factor receptor and c-erbB-2 oncogene product in human ovarian carcinoma.
    Ito K; Sasano H; Ozawa N; Sato S; Silverberg SG; Yajima A
    Int J Gynecol Pathol; 1992 Oct; 11(4):253-7. PubMed ID: 1356938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of heat shock protein 70 expression with estrogen receptor levels in invasive human breast cancer.
    Takahashi S; Mikami T; Watanabe Y; Okazaki M; Okazaki Y; Okazaki A; Sato T; Asaishi K; Hirata K; Narimatsu E
    Am J Clin Pathol; 1994 Apr; 101(4):519-25. PubMed ID: 7909191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators.
    Travis A; Pinder SE; Robertson JF; Bell JA; Wencyk P; Gullick WJ; Nicholson RI; Poller DN; Blamey RW; Elston CW; Ellis IO
    Br J Cancer; 1996 Jul; 74(2):229-33. PubMed ID: 8688326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type 1 protein tyrosine kinases in benign and malignant breast lesions.
    Suo Z; Emilsen E; Tveit KM; Nesland JM
    Histopathology; 1998 Dec; 33(6):514-21. PubMed ID: 9870145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells.
    Sasano H; Date F; Imatani A; Asaki S; Nagura H
    Hum Pathol; 1993 Jun; 24(6):584-9. PubMed ID: 8099338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. neu oncogene protein and epidermal growth factor receptor are independently expressed in benign and malignant breast tissues.
    Tsutsumi Y; Naber SP; DeLellis RA; Wolfe HJ; Marks PJ; McKenzie SJ; Yin S
    Hum Pathol; 1990 Jul; 21(7):750-8. PubMed ID: 1972932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
    Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
    J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunohistochemical study of c-erbB-2 proto-oncogene product in prostatic cancer].
    Kokuho M; Yoshiki T; Hamaguchi A; Okada Y; Tomoyoshi T; Higuchi K
    Nihon Hinyokika Gakkai Zasshi; 1993 Oct; 84(10):1872-8. PubMed ID: 7902885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
    Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
    Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.
    Royuela M; de Miguel MP; Ruiz A; Fraile B; Arenas MI; Romo E; Paniagua R
    Eur Cytokine Netw; 2000 Mar; 11(1):119-27. PubMed ID: 10705309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.
    Myers RB; Srivastava S; Oelschlager DK; Grizzle WE
    J Natl Cancer Inst; 1994 Aug; 86(15):1140-5. PubMed ID: 7913137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostate tissues.
    Cohen DW; Simak R; Fair WR; Melamed J; Scher HI; Cordon-Cardo C
    J Urol; 1994 Dec; 152(6 Pt 1):2120-4. PubMed ID: 7525998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues.
    Ibrahim GK; Kerns BJ; MacDonald JA; Ibrahim SN; Kinney RB; Humphrey PA; Robertson CN
    J Urol; 1993 Jan; 149(1):170-3. PubMed ID: 7678041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.